Autres langues Annovis Bio, Inc.

Actions

ANVS

US03615A1088

Marché Fermé - Nyse Autres places de cotation 22:00:02 26/04/2024			Varia. 5j.	Varia. 1 janv.
18,01 ^USD	+32,43%		+79,03%	-3,69%

01/04	Annovis annonce une publication qui conforte la compréhension du mécanisme d'action du buntanetap chez l'homme	CI
29/03	Annovis Bio, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Annovis Bio : Material Agreement - Form 8-K	26/04
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	02/04
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	01/04
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	01/04
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Top Midday Gainers	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	20/03
Annovis Bio : Material Event - Form 8-K	20/03
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	15/03
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	15/03
North American Morning Briefing : Fed's Preferred -2-	29/02
Annovis Bio Shares Fall After Downgrade From Brookline Capital	28/02
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27/02
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27/02
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	15/02
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	14/02
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	14/02
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Annovis Bio, Inc.

Actions

ANVS

US03615A1088

Autres langues

Filtres